Good morning, and welcome to the special meeting of stockholders of Akero Therapeutics Inc. I would like to turn the call over to Dr. Andrew Cheng, President and Chief Executive Officer of Akero. Sir, please go ahead. Thank you, Operator, and good morning, everyone. Thank you for attending the special meeting of stockholders of Akero Therapeutics. The meeting will be conducted in accordance with the rules of conduct that are posted to this web portal. It is now 11:00 A.M. Eastern Time, and this meeting is officially called to order. The business before this meeting is described in the proxy statement for this meeting, in accordance with the certificate of incorporation and the bylaws of Akero. In attendance today is Natalie Hairston, a representative of American Election Services, who has taken an oath to act as the Inspector of Election for this meeting. The oath of the Inspector of Election will be filed with the minutes of this meeting. As the Inspector of Election, Ms. Hairston is responsible for canvassing the votes on the matters noted in the proxy statement for this meeting and reporting the results. All proxies received by Akero management have been delivered to the Inspector of Election. The Board of Directors set November 7, 2025, as the record date for this meeting, and we have a list of our stockholders of record as of that date available on the web portal during this meeting. A duplicate stockholder list has been on file in our headquarters for the past 10 days and has been available for inspection by any requesting stockholder. A copy of the notice of this meeting, the proxy statement for this meeting, and an affidavit of mailing, which confirms the notice and proxy statement for this meeting, were mailed to Akero stockholders beginning November 7, 2025. It is also available on the web portal during this meeting. The notice and proxy statement for this meeting were sent to all stockholders of record as of the record date, and notice of this meeting has been given in accordance with the certificate of incorporation and bylaws of the company. Stockholders attending this meeting via the web portal may vote their shares online in real time until the polls are closed. If you have already sent in a proxy in a timely manner, your vote will be counted automatically without any further action on your part. If you are eligible to vote and have not submitted your proxy or wish to change your vote, you may vote virtually by clicking on the Vote Here button on the web portal. After the voting has been completed on all matters on the agenda, we will close the polls, and the Inspector of Election will report a preliminary report. Please note that no one attending this meeting via the web portal is permitted to use any audio or video recording device. We will now proceed with the formal business of this meeting. I will start by reporting on the existence of a quorum for this meeting. I have been informed by the Inspector of Election that the number of shares present virtually or by proxy constitutes a majority of the outstanding shares among common stock of Akero entitled to vote as of the record date of November 7, 2025. We therefore have a quorum, and the special meeting is duly constituted. There being a quorum present, I will proceed to the proposals to be considered by stockholders at this meeting. The first item of business stated in the notice of special meeting of stockholders included in the proxy statement is to adopt the Agreement and Plan of Merger dated October 9, 2025, by and among Akero, Novo Nordisk A/S, and NN Invest Sub Incorporated, including the form of Contingent Value Rights agreement to be entered into at or immediately prior to the effective time of merger by a direct or indirect wholly owned subsidiary of Novo Nordisk, as stated in the CVR agreement. The rights agent selected by Novo Nordisk and reasonably acceptable to Akero and solely with respect to Section 6.11 of the CVR agreement, Novo Nordisk, pursuant to the terms of the merger, NN Invest Sub Incorporated will merge with and into Akero, with Akero surviving the merger as a wholly owned subsidiary of Novo Nordisk. We will call this proposal the merger proposal. The next item of business is approval on an advisory non-binding basis of the payment of certain compensation that may be paid or become payable to Akero to its named executive officers in connection with the merger. We will call this proposal the compensation proposal. Now that the proposals have been properly presented, we can move on to the vote. It is now 11:05 A.M. Eastern Time on December 2, 2025, and I declare the polls open for each matter to be voted at the special meeting. If you are voting today, you must submit your votes at this time on the web portal in order for them to be counted by the Inspector of Election. The Inspector of Election will not accept proxies, ballots, votes, or any changes or revocations of votes submitted after the closing of the polls. The Inspector of Election will canvass the votes in accordance with their standard procedures, and the results of the balloting will be certified by the Inspector of Election. After certification, Akero will publicly announce the results of the voting on items presented at the meeting. We will now pause to allow all stockholders to cast their votes. It is now 11:07 A.M. Eastern Time on December 2, 2025, and I declare that the polls for each matter to be voted on at this special meeting are now closed. The Inspector of Election has delivered a preliminary report of the voting, which shows, with respect to Proposal One, the merger proposal has been approved by the holders of a majority of the outstanding shares of Akero common stock until the vote on the such proposal. With respect to Proposal Two, the compensation proposal has been approved by the holders of a majority of the outstanding shares of Akero common stock, properly voted for or against the compensation proposal. Because the proposal related to the adoption of the merger has been approved, we do not need to present the third proposal described in the proxy statement related to the adjournment of this meeting to solicit additional proxies in favor of adoption of the merger agreement. I hereby request that the final report of the Inspector of Election be filed with the meeting with the minutes of this meeting. This completes the business to be conducted at this meeting. As there are no other matters to come before the meeting, this meeting shall now be adjourned. Thank you for your attendance at this meeting and support of Akero. Ladies and gentlemen, this concludes today's meeting. You may now disconnect.